Results 81 to 90 of about 8,977,908 (300)

Statistics of infections with diversity in the pathogenicity [PDF]

arXiv, 2004
The statistics of outbreaks in a model for the propagation of meningococcal diseases is analyzed, taking into account the possibility that the population is fragmented into weakly connected patches. It is shown that, depending on the size of of the sample studied, the ratio between the variance and the mean of infected cases can vary from one (Poisson ...
arxiv  

EPYSQLI (SB12; Biosimilar to Reference Eculizumab) in Asian and Non‐Asian Patients With Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial

eJHaem, Volume 6, Issue 2, April 2025.
ABSTRACT Introduction SB12 demonstrated equivalence to reference eculizumab (ECU) in complement inhibitor‐naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) in the previous randomized, double‐blind, multi‐national, crossover, Phase III study.
Jun Ho Jang, Ciprian Tomuleasa, Hanna Oliynyk, Theerin Lanamtieng, Jihye Park, Younsoo Kim, Jinah Jung, Paola Russo, Soo Min Lim, Régis Peffaultde Latour   +9 more
wiley   +1 more source

Meningococcal conjugate vaccines: optimizing global impact

Infection and Drug Resistance, 2011
Andrew Terranella1,2, Amanda Cohn2, Thomas Clark2 1Epidemic Intelligence Service, Division of Applied Sciences, Scientific Education and Professional Development Program Office, 2Meningitis and Vaccine Preventable Diseases Branch, National Center for ...
Terranella A, Cohn A, Clark T
doaj  

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1820 (Tarperprumig) in Healthy Adults: Results of a Phase I Study

Clinical and Translational Science, Volume 18, Issue 4, April 2025.
ABSTRACT Properdin is an endogenous positive regulator of the complement alternative pathway (AP). Tarperprumig (ALXN1820), a novel humanized bispecific antibody, binds properdin and albumin and is being developed to treat complement‐mediated diseases.
Avner Sandhu, Tong Shen, Paz Martin Herrero, Chao‐Xing Yuan, Samirah Qureshi, Xiaoyu Jiang, Ye Sheng, Christoph Gasteyger, Yang Dai   +8 more
wiley   +1 more source

Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a College—Rhode Island, 2015–2016

Clinical Infectious Diseases, 2017
Background Serogroup B meningococcal disease caused 7 US university outbreaks during 2013-2016. Neisseria meningitidis can be transmitted via asymptomatic nasopharyngeal carriage.
Heidi M. Soeters, M. Whaley, N. Alexander-Scott, K. V. Kanadanian, Jessica R Macneil, S. Martin, L. McNamara, Kenneth Sicard, C. Vanner, Jeni T. Vuong, Xin Wang, U. Bandy, Manisha Patel   +12 more
semanticscholar   +1 more source

Meningococcal disease serogroup C

Risk Management and Healthcare Policy, 2012
Félix O Dickinson1, Antonio E Pérez1, Iván E Cuevas21Department of Epidemiology, “Pedro Kourí” Institute, Havana, Cuba; 2Pharmacovigilance Group, Finlay Institute, Havana, CubaAbstract ...
Cuevas IE, Pérez AE, Dickinson FO   +2 more
doaj  

Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.

PLoS ONE, 2020
IntroductionEculizumab is a licensed treatment for several rare, complement-mediated diseases. Eculizumab use is associated with an approximately 2,000-fold increased meningococcal disease risk.
Catherine H Bozio, Cheryl Isenhour, Lucy A McNamara   +2 more
doaj   +1 more source

Phase diagram of epidemic spreading - unimodal vs. bimodal probability distributions [PDF]

, 2009
The disease spreading on complex networks is studied in SIR model. Simulations on empirical complex networks reveal two specific regimes of disease spreading: local containment and epidemic outbreak. The variables measuring the extent of disease spreading are in general characterized by a bimodal probability distribution.
arxiv   +1 more source

Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension

European Journal of Neurology, Volume 32, Issue 4, April 2025.
Ravulizumab demonstrated clinically meaningful and durable efficacy and safety in adults with anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis in the CHAMPION MG open‐label extension (OLE) study. Improvements from baseline in MG‐ADL, QMG, and MG‐QOL15r total scores, and the NeuroQOL Fatigue subscale scores achieved in ...
Tuan H. Vu, Renato Mantegazza, Djillali Annane, Masahisa Katsuno, Andreas Meisel, Michael W. Nicolle, Vera Bril, Rasha Aguzzi, Glen Frick, James F. Howard Jr, the CHAMPION MG Study Group   +10 more
wiley   +1 more source

Increased Risk for Meningococcal Disease Among Men Who Have Sex With Men in the United States, 2012–2015

Clinical Infectious Diseases, 2017
Background Several clusters of serogroup C meningococcal disease among men who have sex with men (MSM) have been reported in the United States in recent years. The epidemiology and risk of meningococcal disease among MSM is not well described.
Temitope A Folaranmi, C. Kretz, H. Kamiya, Jessica R Macneil, M. Whaley, Amy E. Blain, Mike Antwi, M. Dorsinville, M. Pacilli, Shamika S. Smith, R. Civen, Van P Ngo, K. Winter, K. Harriman, Xin Wang, V. Bowen, Manisha Patel, S. Martin, L. Misegades, Sarah A. Meyer   +19 more
semanticscholar   +1 more source